Losmapimod
Losmapimod (GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pKis of 8.1 and 7.6 for p38α and p38β, respectively[1].
Product Specifications
CAS Number
585543-15-3
Product Name Alternative
GSK-AHAB; GW856553X; SB856553
UNSPSC
12352005
Hazard Statement
H361
Target
Autophagy; p38 MAPK
Type
Reference compound
Related Pathways
Autophagy; MAPK/ERK Pathway
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cancer
Assay Protocol
https://www.medchemexpress.com/Losmapimod.html
Concentration
10mM
Purity
99.94
Solubility
DMSO : 27.5 mg/mL (ultrasonic) |Ethanol : 33.33 mg/mL (ultrasonic)
Smiles
CC1=C(C2=NC=C(C(NCC(C)(C)C)=O)C=C2)C=C(C(NC3CC3)=O)C=C1F
Molecular Formula
C22H26FN3O2
Molecular Weight
383.46
Precautions
H361
References & Citations
[1]Willette RN, et al. Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. J Pharmacol Exp Ther. 2009 Sep;330 (3) :964-70.|[2]Zhang XM, et al. Suppression of mitochondrial fission in experimental cerebral ischemia: The potential neuroprotective target of p38 MAPK inhibition. Neurochem Int. 2015 Nov;90:1-8.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![Rabbit Polyclonal UNC13C Antibody [DyLight 405]](https://cdn.genprice.uk/genprice/uk/genprice2.webp)
